Global Women's Health Academy

Spontaneous Preterm Birth: How Are Clinicians Managing At-Risk Women?

With ACOG changing the definition of preterm birth and the available efficacy and safety data for current progestogen agents, preterm birth is a qu...

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    With ACOG changing the definition of preterm birth and the available efficacy and safety data for current progestogen agents, preterm birth is a quickly advancing field for practicing physicians to effectively manage. This activity will discuss the risks and benefits of to the clinical management of women at risk for preterm birth and the redefinition of “term pregnancy”. 

    Join Dr. Cynthia Gyamfi-Bannerman while she discusses clinical management of women at-risk for spontaneous preterm birth.

    In January 2017, after the original release of this activity, The Society for Maternal Fetal Medicine Publications Committee made public an SMFM Statement entitled: The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Click here to access this article.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational program

    Cynthia Gyamfi-Bannerman, BSc, MSc, MD, FACOG
    Associate Professor of Obstetrics & Gynecology
    Director of the Maternal-Fetal Medicine Fellowship Program
    Medical Director of the Perinatal Clinics
    Columbia University Medical Center
    New York, NY

    Dr. Gyamfi-Bannerman has nothing to disclose.

    Matt Birnholz, MD

    Dr. Birnholz has nothing to disclose.


    • Sean T. Barrett has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert Schneider has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Describe the risk factors for and pathogenesis of preterm birth (PTB), as well as the economic burden/cost of illness.
    • Discuss the available efficacy and safety data for the current progestogen agents, and the relevance of those data to FDA approval.
    • Demonstrate understanding of the ACOG/SMFM redefinition of “term pregnancy”.
    • Incorporate strategies for providing optimal clinical management to women at risk for PTB, based on SMFM and ACOG recommendations.
    • Define the differences in quality standards between pharmacy-compound 17P and those of the FDA-approved product.
  • Target Audience

    The target audience for this activity includes obstetrician/gynecologists, maternal fetal medicine specialists, nurse practitioners, physician assistants, and certified nurse midwives.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from AMAG Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required